Research and Clinical Trials

Trial of CPX-351 Liposome Injection versus Intensive Salvage Therapy for Relapsed Acute Myeloid Leukemia
Brief Description  
This study will estimate the efficacy of CPX-351 (Cytarabine:Daunorubicin in liposomal formulation) compared with standard of care salvage therapy in adult patients less than 61 years of age with acute myeloid leukemia in first relapse after complete remission of more than one month.
Who may be Eligible  
Subjects between the ages of 18 and 60 years of age with pathologic confirmation of relapsed Acute Myeloid Leukemia
  • Complete remission of more than one month after previous therapy
  • Ambulatory and able to carry out work
  • Good cardiac function (by ECHO or MUGA procedure)
  • Less than 368mg/m2 previous anthracycline (e.g., daunorubicin) exposure
Must have adequate blood lab values for:
  • Liver function
  • Kidney function
Must agree to practice effective contraception during study period (12-15 months) and for 3 months afterward
IRB Number  
Principal Investigator  
Miller, David

For More Information, Contact  Louise  , Kent
Phone:  (704) 355-7430  Fax:  (704) 355-1188  
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive, Ste 600 Charlotte, NC 28204